News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) Announces Results From Phase 2 Study Showing Reduction In Atrial Fibrillation Burden With The Investigational Combination Of Ranolazine And Low-Dose Dronedarone


5/12/2014 9:13:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden (AFB) in patients with paroxysmal atrial fibrillation (AF). In HARMONY, the combination of ranolazine and low-dose dronedarone provided greater reductions in AFB from baseline than either therapy used alone. Detailed results from the study (Abstract #LB03-05) will be presented today during a late-breaking clinical trials session at the annual meeting of the Heart Rhythm Society in San Francisco.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES